Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Last month the DISRUPT CAD III investigators, led by co-PIs Drs. Dean Kereiakes and Jonathan Hill, published in the American Heart Journal the trial design and rationale paper titled, “Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial.”
Topics: Coronary IVL, DISRUPT CAD, Coronary Clinical Data
Prof. Carlo Di Mario, Director of Structural Interventional Cardiology at the Careggi University Hospital in Florence, Italy, and other cardiologists in Florence recently published their initial real-world experience when using intravascular imaging while treating coronary lesions with Intravascular Lithotripsy (IVL).
Topics: Coronary IVL, Coronary Clinical Data, Shockwave C2, CAD Applications - Eccentric Lesions
In case you weren’t able to make it to EuroPCR’s e-Course last week, you missed a great discussion among some of coronary IVL’s most knowledgeable operators about how they’re using the technology in the real-world setting. Lucky for you, we’ve included the sponsored roundtable discussion below featuring Drs. Benjamin Honton (FR), Javier Escaned (ES) and Michael Lee (HK). We hope you enjoy hearing their perspectives from across Europe and Asia.
Topics: Coronary IVL, Coronary Cases, Coronary Clinical Data, Shockwave C2, Coronary Conferences, CAD Applications - Eccentric Lesions
Recently, Dr. James Spratt, consultant cardiologist at St George's University NHS Trust in London and founder of Optima Education, and other leading UK cardiologists published their experience with Intravascular Lithotripsy (IVL) in the left main in EuroIntervention: Intravascular lithotripsy for the treatment of calcific distal left main disease.
Topics: Coronary IVL, Coronary Cases, Coronary Clinical Data, Shockwave C2
At Shockwave, we’re committed to the creation of sound clinical evidence to support the adoption and long-term utilization of our technology. This includes a balance of high-quality Shockwave-sponsored and investigator-initiated research studies to advance the knowledge of our technology’s performance in daily practice.
While you can read more about our company-sponsored clinical trials on the website here, there hasn’t been a good resource for our customers to understand what investigator-initiated studies we’re also supporting…until now.
Topics: Coronary Clinical Data, Shockwave C2
It’s that time of year where there seems to be a countdown for everything – Top 100 Songs, Top Baby Names, Top 10 Sports Moments of 2019 – We wanted to get in on the fun too and here it is… Top 5 Coronary IVL Publications from 2019!
Topics: Coronary Clinical Data
The complete DISRUPT CAD II study findings have been published by the AHA’s journal, Circulation: Cardiovascular Interventions, and while it’s definitely worth the full read, we know that sometimes there just aren’t enough hours in the day. For a quick synopsis, we took the liberty to summarize some of the key data points into a visual-friendly infographic for you to review some of the study’s most important findings.
Topics: Coronary Clinical Data, Shockwave C2
For international customers currently using our coronary technology, we’re happy to report that coinciding with its presentation at TCT 2019 today, the DISRUPT CAD II study has also been simultaneously published by the AHA journal, Circulation: Cardiovascular Interventions.
Topics: Coronary Clinical Data, Shockwave C2
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
